Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Trinity: Deep Dive
From Static Insights to Always On Intelligence
There is a growing paradox in life sciences commercialization: more data and more research than ever, yet many critical decisions still rely on static decks, siloed databases, and one time studies that go stale almost immediately. Commercial, medical, and market access...
Trinity: Deep Dive
The AI Context Layer: The Missing Link in AI-Ready Data
Most commercial life sciences organizations have invested heavily in data. They have lakehouses, harmonized data feeds, and dashboard environments like Power BI, Tableau, and Snowflake that teams rely on daily. These tools already carry semantic models: metric definitions, schema relationships, and...
Market Access Trends 2026
How China’s Layered Access System and Real-World Evidence Are Changing Market Access
China is evolving beyond a single public reimbursement model toward a layered access system that combines national coverage, commercial funding, and early access programs. In 2025, these changes began to reshape how manufacturers think about pricing, evidence, and launch sequencing. In...
Market Access Trends 2026
How Four Pillars Are Shaping Latin America and MENA Market Access
Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models, and...
Market Access Trends 2026
How Regulatory–HTA Convergence Is Reshaping European Market Access
Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring the...
Market Access Trends 2026
How MFN and Direct-to-Consumer Models Are Rewiring US Market Access
Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access 2026:...
